March 24, 2021
An audit has identified that in Northamptonshire there are some patients on long term amiodarone who are not under cardiology follow up.
The NICE Clinical Guideline on Atrial Fibrillation: Management (CG180) states that amiodarone should not be used long term for rate control in atrial fibrillation (AF) and that where used for rhythm control before or after electrical cardioversion it should only be for up to 12 months.
If it is prescribed long term patients should remain under cardiology supervision. This is due to the potential toxicity of amiodarone in long term use.
A Tablet Press Extra with guidance for referring these patients for cardiology follow up has been agreed with the cardiology departments at KGH and NGH.
As this is a significant patient safety issue these patients should be referred as soon as possible.
However the referrals will be triaged and it may be some months before all patients have been offered appointments.
It is likely that most of these reviews will be conducted virtually.